Gammadelta T cells in cancer immunotherapy

Gammadelta T cells in Cancer Immunotherapy shows how the potential of ?d T-cells can effectively be translated into clinical benefit in cancer immunotherapies. With a strong focus on finding alternatives to current T cell mediated cancer immunotherapies, the book can also be used as a baseline initial introduction to the field of gamma delta immunotherapy. In 13 chapters Gammadelta T cells in cancer immunotherapy describes different approaches to a specific model of gammadelta immunotherapy including 'delta one T' (DOT) and Allogeneic CAR. It describes the rationale for the use of gamma delta cells in immunotherapy, strategies, therapies, and cancer treatment.

Gammadelta T cells in Cancer Immunotherapy answers the growing interest in the scientific and medical community in general immunotherapy and familiarizes end users with the basic biology of gammadelta T cells, the pre-clinical studies implying their utility in immunotherapy, and with the studies of clinical applications of different forms of gammadelta T cell immunotherapeutic. modalities. Contents will help both basic scientists and clinicians understand how to overcome hurdles inherent to current forms of CAR T cell immunotherapy

• Provides a baseline introduction to the field of gamma delta immunotherapy
• Gives a broad overview of the progress in the field of gammadelta immunotherapy using concrete examples
• Each chapter describes an approach to a specific model of gammadelta immunotherapy
• Edited by Ilan Bank, author of the first paper describing the discovery of a novel type of human thymocyte in forming the basis of recognition of the second T cell receptor (gammadelta) and the subsets of T cells expressing these receptors, known now as gammadelta T cells